Self-assembling DNA hydrogel-based delivery of immunoinhibitory nucleic acids to immune cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 1, 2016, Pages 123-130

  Nishida, Yu ^a   Ohtsuki, Shozo ^a   Araie, Yuki ^a   Umeki, Yuka ^a   Endo, Masayuki ^b   Emura, Tomoko ^a   Hidaka, Kumi ^a   Sugiyama, Hiroshi ^a,b   Takahashi, Yuki ^a   Takakura, Yoshinobu ^a   Nishikawa, Makiya ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

CpG motif; DNA hydrogel; Immunoinhibitory oligodeoxynucleotide; Toll like receptor 9

Indexed keywords

CELLS; CHEMICAL ACTIVATION; CYTOLOGY; ELECTROPHORESIS; HYDROGELS; MACROPHAGES; NUCLEIC ACIDS;

AUTOIMMUNE DISEASE; CPG MOTIF; FLOW CYTOMETRY ANALYSIS; OLIGODEOXYNUCLEOTIDES; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRO-INFLAMMATORY CYTOKINES; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTORS;

DNA;

CPG OLIGODEOXYNUCLEOTIDE; DNA; INTERLEUKIN 6; NUCLEIC ACID; OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; HYDROGEL; IMMUNOSUPPRESSIVE AGENT; NANOCAPSULE; TLR9 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL LINE RAW 264.7; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FLOW CYTOMETRY; HYDROGEL; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; ANIMAL; CELL LINE; CHEMISTRY; CRYSTALLIZATION; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MACROPHAGE; PROCEDURES; ULTRASTRUCTURE;

ANIMALS; CELL LINE; CRYSTALLIZATION; DENDRITIC CELLS; DNA; HUMANS; HYDROGELS; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGES; MICE; NANOCAPSULES; TOLL-LIKE RECEPTOR 9;

EID: 84957107785     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.08.004     Document Type: Article

References (30)

1. Latz E., Schoenemeyer A., Visintin A., Fitzgerald K.A., Monks B.G., Knetter C.F., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004, 5:190-198.
2. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
3. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
4. Sparwasser T., Miethke T., Lipford G., Erdmann A., Häcker H., Heeg K., et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol 1997, 27:1671-1679.
5. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996, 93:2879-2883.
6. Krug A., Rothenfusser S., Hornung V., Jahrsdörfer B., Blackwell S., Ballas Z.K., et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001, 31:2154-2163.
7. Schubert C. Boosting our best shot. Nat Med 2009, 15:984-988.
8. Yasuda H., Leelahavanichkul A., Tsunoda S., Dear J.W., Takahashi Y., Ito S., et al. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 2008, 294:F1050-F1058.
9. Tian J., Avalos A.M., Mao S.-Y., Chen B., Senthil K., Wu H., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496.
10. Stunz L.L., Lenert P., Peckham D., Yi A.-K., Haxhinasto S., Chang M., et al. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol 2002, 32:1212-1222.
11. Ashman R.F., Goeken J.A., Lenert P.S. Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9. Int Immunopharmacol 2011, 11:1032-1037.
12. Ashman R.F., Goeken J.A., Drahos J., Lenert P. Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol 2005, 17:411-420.
13. Latz E., Verma A., Visintin A., Gong M., Sirois C.M., Klein D.C., et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007, 8:772-779.
14. Ohto U., Shibata T., Tanji H., Ishida H., Krayukhina E., Uchiyama S., et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 2015, 520:702-705.
15. Matsuoka N., Nishikawa M., Mohri K., Rattanakiat S., Takakura Y. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides. J Control Release 2010, 148:311-316.
16. Mohri K., Takahashi N., Nishikawa M., Kusuki E., Shiomi T., Takahashi Y., et al. Design and development of nanosized DNA assemblies in polypod-like structures as efficient vehicles for immunostimulatory CpG motifs to immune cells. ACS Nano 2012, 6:5931-5940.
17. Nishikawa M., Mizuno Y., Mohri K., Matsuoka N., Rattanakiat S., Takahashi Y., et al. Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice. Biomaterials 2011, 32:488-494.
18. Nishikawa M., Ogawa K., Umeki Y., Mohri K., Kawasaki Y., Watanabe H., et al. Injectable, self-gelling, biodegradable, and immunomodulatory DNA hydrogel for antigen delivery. J Control Release 2014, 180:25-32.
19. Gerhart J., Baytion M., DeLuca S., Getts R., Lopez C., Niewenhuis R., et al. DNA dendrimers localize MyoD mRNA in presomitic tissues of the chick embryo. J Cell Biol 2000, 149:825-834.
20. Iannitti T., Morales-Medina J.C., Palmieri B. Phosphorothioate oligonucleotides: effectiveness and toxicity. Curr Drug Targets 2014, 15:663-673.
21. Endo M., Katsuda Y., Hidaka K., Sugiyama H. Regulation of DNA methylation using different tensions of double strands constructed in a defined DNA nanostructure. J Am Chem Soc 2010, 132:1592-1597.
22. Lenert P. Inhibitory oligodeoxynucleotides-therapeutic promise for systemic autoimmune diseases?. Clin Exp Immunol 2005, 140:1-10.
23. Roberts T.L., Dunn J.A., Terry T.D., Jennings M.P., Hume D.A., Sweet M.J., et al. Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J Immunol 2005, 175:3569-3576.
24. Uno S., Nishikawa M., Mohri K., Umeki Y., Matsuzaki N., Takahashi Y., et al. Efficient delivery of immunostimulatory DNA to mouse and human immune cells through the construction of polypod-like structured DNA. Nanomedicine 2014, 10:765-774.
25. Peter M., Bode K., Lipford G.B., Eberle F., Heeg K., Dalpke A.H. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology 2008, 123:118-128.
26. Ashman R.F., Goeken J.A., Latz E., Lenert P. Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. Int Immunol 2011, 23:203-214.
27. Plitas G., Burt B.M., Nguyen H.M., Bamboat Z.M., DeMatteo R.P. Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. J Exp Med 2008, 205:1277-1283.
28. Patole P.S., Zecher D., Pawar R.D., Gröne H.-J., Schlöndorff D., Anders H.-J. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 2005, 16:3273-3280.
29. Oka T., Hikoso S., Yamaguchi O., Taneike M., Takeda T., Tamai T., et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012, 485:251-255.
30. Zhang Y., Lee A.S., Shameli A., Geng X., Finegood D., Santamaria P., et al. TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. J Immunol 2010, 184:5645-5653.